D. E. Shaw & Co., Inc. Avalo Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.0 - $10.45 $338,037 - $1.18 Million	-112,679 Reduced 35.17%	207,683 $104,000
Q1 2022 May 16, 2022	SELL	$7.57 - $21.72 $110,976 - $318,415	-14,660 Reduced 4.38%	320,362 $232,000
Q4 2021 Feb 14, 2022	BUY	$19.68 - $28.68 $3.18 Million - $4.63 Million	161,598 Added 93.18%	335,022 $570,000
Q3 2021 Nov 15, 2021	BUY	$26.16 - $40.68 $4.54 Million - $7.05 Million	173,424 New	173,424 $378,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $103M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.